Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NEK2 | P51955 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238160 | 0.82 | KDM4E (0.60) | MALT1KDM4ECYP2C19NEK2KMT2A | |
| SCHEMBL2421306 | 0.80 | MALT1 (0.70) | MALT1KDM4ECYP2C19NEK2KMT2A | |
| SCHEMBL4879872 | 0.79 | KDM4E (0.60) | MALT1KDM4ECYP2C19NEK2KMT2A | |
| SCHEMBL4524152 | 0.79 | NEK2 (0.67) | MALT1KDM4ECYP2C19NEK2KMT2A | |
| SCHEMBL29086088 | 0.78 | SLC2A1 (0.52) | MALT1CYP2C19 | |
| SCHEMBL30585959 | 0.78 | SLC2A1 (0.52) | MALT1CYP2C19 | |
| SCHEMBL3104049 | 0.77 | NEK2 (0.59) | MALT1KDM4ECYP2C19NEK2KMT2A | |
| SCHEMBL2812388 | 0.76 | RBP4 (0.49) | MALT1KDM4ECYP2C19KMT2A | |
| SCHEMBL27815937 | 0.76 | CYP1A2 (0.51) | MALT1KDM4ECYP2C19 | |
| SCHEMBL1252470 | 0.76 | TRPV1 (0.66) | MALT1KDM4ECYP2C19NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401279-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | Vantia Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | MALT1 4857/4885KDM4E 2389/4885CYP2C19 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.